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Optogenetic Peripheral Nerve 
Immunogenicity
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Optogenetic technologies have been the subject of great excitement within the scientific community 
for their ability to demystify complex neurophysiological pathways in the central (CNS) and peripheral 
nervous systems (PNS). The excitement surrounding optogenetics has also extended to the clinic 
with a trial for ChR2 in the treatment of retinitis pigmentosa currently underway and additional trials 
anticipated for the near future. In this work, we identify the cause of loss-of-expression in response 
to transdermal illumination of an optogenetically active peroneal nerve following an anterior 
compartment (AC) injection of AAV6-hSyn-ChR2(H134R) with and without a fluorescent reporter. Using 
Sprague Dawley Rag2−/− rats and appropriate controls, we discover optogenetic loss-of-expression 
is chiefly elicited by ChR2-mediated immunogenicity in the spinal cord, resulting in both CNS motor 
neuron death and ipsilateral muscle atrophy in both low and high Adeno-Associated Virus (AAV) 
dosages. We further employ pharmacological immunosuppression using a slow-release tacrolimus 
pellet to demonstrate sustained transdermal optogenetic expression up to 12 weeks. These results 
suggest that all dosages of AAV-mediated optogenetic expression within the PNS may be unsafe. 
Clinical optogenetics for both PNS and CNS applications should take extreme caution when employing 
opsins to treat disease and may require concurrent immunosuppression. Future work in optogenetics 
should focus on designing opsins with lesser immunogenicity.
The clinical excitement surrounding optogenetics is eminently justified – a single, precise injection transforms 
a patient’s genome, making an anatomically targeted subset of neurons responsive to external control. Unlike 
electrical stimulation, the molecular specificity associated with unique promoters can limit off-target effects. 
Opsin engineering has conferred a toolbox of choices, each with its own favorable characteristics – photocurrent, 
wavelength, kinetics, and illumination sensitivity can be tuned to an application’s needs1,2. Lastly, an opsin’s DNA 
sequence is relatively short allowing it to be easily packaged within an AAV for stable delivery.
Using optogenetics to treat retinitis pigmentosa became the first clinical application, with chronic pain, cardiac 
pacing, and other PNS applications currently under investigation. Of currently available opsins, ChR2(H134R) 
was chosen for this study because it is one of the most commonly used opsins in the PNS1 and because it has 
optimal PNS properties including expression levels, kinetics, and photocurrent3. In March 2016, Retrosense 
Therapeutics (now Allergan) delivered the first in-human optogenetic therapy using AAV-ChR2 as part of an 
investigational new drug study. Gensight and Circuit Therapeutics are also working on optogenetic clinical mod-
els with potential in-human applications in the near future. These companies have largely been operating in the 
footsteps of Spark Therapeutics, which received FDA approval to market their RPE65 rAAV for retinal dystrophy 
in December 2017. Despite these rapid developments in rAAV and optogenetic deployment, academic research 
in the time-course, safety, and systemic tolerance of rAAV-administered optogenetic therapies within both PNS 
and CNS has lagged behind.
A limited number of previous studies describe optogenetic cytotoxicity and abnormalities; only a few dis-
cuss optogenetic expression time course in detail4,5. Axonal blebbing or puncta have been shown in response to 
both AAV and lentiviral delivered ChR26 or NpHR7 under the αCaMKII promoter in the cortex in vivo and in 
acute brain slices from transgenic Thy1-NpHR mice8. While these abnormalities are associated with only a slight 
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loss-of-function, they are directly attributed to high opsin production, endoplasmic reticulum (ER) retention, 
and a membrane trafficking defect. Other reports have focused on the opsin’s toxic effect on the cell membrane. 
High opsin expression has been shown to increase membrane capacitance9 and can lead to a loss of membrane 
integrity10.
In addition to cytotoxicity, phototoxicity has been shown in both retinal11 and cortical tissues12, where cellular 
damage is elicited by the high illumination intensities required to depolarize opsins. In an opsin-independent 
manner, the mechanism may be thermal13, although fluorescent reporters are also known to generate reactive 
oxygen species (ROS) directly in response to illumination; these ROS can elicit structural and DNA damage, 
and at high levels, initiate apoptosis14. Unlike phototoxicity, optogenetic excitotoxicity is directly related to 
light-induced opsin activation. The mechanism underlying excitotoxicity has been described as a process of unde-
sirable intracellular acidification due to selective proton permeability15 and/or mitochondria-mediated apop-
tosis16. In the study proposing the latter, chronic blue light activation was employed to eliminate completely a 
resilient line of human melanoma cells selectively expressing ChR2(D156A)16.
Unlike ChR2 toxicity, AAV specific immunogenicity has been described in numerous studies. These studies 
range from the presence of anti-AAV neutralizing antibodies in human clinical trials to titer-specific inflam-
matory responses to AAV spinal cord microinjections in mice1,17–19 to anti-AAV antibodies in optogenetics20. 
Multiple strategies have been proposed to combat the immune response in AAV-mediated gene therapy including 
pharmacological intervention, dosing management, capsid decoys, and biomolecular engineering of AAV cap-
sids19,21. In addition to cellular AAV responses, GFP cytotoxicity and immunogenicity have been described in vivo 
and in vitro22,23, although evidence suggests YFP is less cytotoxic than GFP24.
While two groups have studied immune responses specific to ChR2 within therapeutic optogenetics for 
blindness, neither group has reported significant immunogenic findings. Each group performs a biodistribu-
tion, an ocular toxicity study, and a systemic immunity study for either rAAV8-mGRM6-SV40-ChR2-heGFP or 
AAV2-CAG-ChR2-Venus intravitreal and/or subretinal injections20,25. Additional tests performed include com-
plete blood counts (CBC), anti-AAV & anti-ChR2 serum antibody testing, and T cell population ratios. Neither 
study identifies any morphological or inflammatory changes in retinae using histology and GFAP, NF-κB, and 
CD45 immunohistochemistry. Systemic immunity studies revealed no toxicity in response to a delayed-type 
hypersensitivity (DTH) test and no abnormalities in CBC panels. Both studies conclude that AAV-ChR2 appears 
to be a safe method for restoration of vision in multiple mouse models of blindness.
While these results largely suggest AAV-ChR2 is safe for retinal transduction under specific promoter and 
injection conditions, several other analyses would be necessary to suggest more broadly the safety of AAV-ChR2 
in mammals. For example, a DTH ear test without the mGRM6 regulatory sequence would allow one to conclude 
a low inflammatory response to the AAV-ChR2 construct as opposed to just the viral capsid itself. Further eval-
uation of the ChR2 DNA > 3X the threshold in muscle and liver may yield insights into whether the mechanism 
is viral clearance as opposed to the reported non-specific cross-contamination, especially given that liver and 
muscle are two of the highest concentration tropisms for AAV8 in intravenous delivery26, and that the liver is a 
key organ for adenovirus clearance27. Further studies of specific T-cell population targets could reveal additional 
insights regarding a potential role of a T-cell mediated immune response, given that systemic CBC levels may not 
change measurably in response to a small, targeted immune response in the eye. Lastly, a study of anti-ChR2 anti-
bodies with a larger sample size and a more detailed time-course would yield stronger insights on the relationship 
of anti-transgene antibodies and expression levels. The above study introduced the possibility of a rat developing 
an anti-ChR2 antibody, but this only occurred in one rat, and not within the time-frame expected for antibody 
development (e.g., time-synced with either the elevated CD4+/CD8+ or CD4+/CD25+ T-cell ratios at 7 days or 
the elevated anti-AAV antibodies between 2 weeks and 2 months post-injection). To close these scientific gaps, 
additional studies are needed to address whether (a) therapeutic ChR2 is indeed immunogenic, (b) if so, this 
immunogenicity results in loss-of-expression, and (c) if so, the cause is the opsin (not AAV or reporter).
As the rat ages, the distance separating the surface of the skin and the nerve increases; in transdermal experi-
ments, light scattering within tissue could prevent sufficient light fluence from reaching the target nerve resulting 
in the false appearance of a loss-of-expression4. Further, since loss-of-expression may be multifactorial, several of 
the above mechanisms may be co-contributing to the findings. For example, cytotoxicity may result in neuronal 
death, which could release some AAV capsid proteins and activate an adaptive immune response.
From the above studies, the precise mechanism behind optogenetic loss of expression over time remains 
unclear. Is the opsin downregulated or degraded over time in an intracellular process? Does this occur at the 
episomal DNA level, the mRNA level, or the protein level? Does high multiplicity of infection (MOI) and mem-
brane blebbing lead to neuronal apoptosis? Does excessive illumination cause acidification-induced cell death? Is 
there an immune response? If so, is it humoral or cell-mediated, innate or adaptive? Is it directed against the AAV 
capsid, the opsin, or the fluorescent reporter?
To date, there have been no studies exhaustively analyzing the precise mechanism behind optogenetic periph-
eral nerve loss of expression. A mechanistic understanding in vivo could both confer enormous benefit to clinical 
trials that employ optogenetics to treat disease and enable previously unfeasible scientific studies that require 
stable, virally delivered optogenetics for a prolonged time-course. We summarize a list of mechanisms in Table 1. 
These mechanisms can be categorized within five groups: direct nerve damage, cytotoxicity, immunogenicity, 
protein downregulation, and anatomical changes. Of the above potential mechanisms, we hypothesize that ChR2 
immunogenicity is the chief cause of the loss of optogenetic expression. Further, we hypothesize that the use of 
pharmacological immunosuppression can extend optogenetic expression longevity. We evaluate this hypothesis 
by comparing the optogenetic expression time-course of several AAV6 vectors with different promoters, with/
without fluorescent reporters, and within wild-type (WT) rats, Rag2−/− rats, and WT rats treated with tacrolimus, 
while performing bloodwork, histology, and gross anatomical observations to support the analysis.
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Results
Optogenetic expression time-course not a function of dosage, rate age, or injection location. 
We have previously reported on the loss of transdermal optogenetic expression over time4. To address this issue, 
we first attempted to vary the injection dosage, the location of the injection, and the rat age during the injection to 
see if these variables affected the strength and time course of optogenetic activity levels (Fig. 1a). In line with the 
previous results, we found optogenetic activity levels to be heavily dose-dependent, with transdermal optogenetic 
activity beginning at dosages of 3E10 vp and increasing in strength through 3E12 vp (Fig. 1b). Injecting rats at dif-
ferent ages did not affect the time course of optogenetic activity; however, slightly weaker optogenetic activity was 
noticed in the rats injected over the first 4 weeks, likely due to synaptic pruning at the neuromuscular junction, 
which occurs rapidly in the first two weeks of murine development28. This is particularly apparent in the rats 
injected at 2 weeks as opposed to 2 days postpartum (P2). Additionally, loss of transdermal response appeared 
to occurr faster in the rats targeting the Tibialis Anterior (TA)-only as opposed to the TA & peroneal nerve at 2 
weeks. However, no matter the dosing, timing or location of the injection, all of the rats with the exception of one 
had lost transdermal expression by 10 weeks post-injection (Fig. 1b). Amazingly, this one rat maintained a grad-
ually weakening transdermal expression for up to 72 weeks post-injection, when it was euthanized for unrelated 
reasons (Supplemental Video, Fig. 1d). In the terminal procedure, this rat maintained strong levels of expression 
with direct stimulation of the sciatic and peroneal nerves with different illumination sources (Fig. 1d). However, 
despite this one animal, we could not sustain a long-term transdermal optogenetic response consistently with any 
specific dosing or injection scheme.
Biodistribution suggests viral expression predominately in muscle tissue. The analysis of viral 
vector spread by quantitative PCR on DNA extract from various organs revealed only minor off-target dissemi-
nation (Fig. 1c). Viral DNA was found in high levels in the gastrocnemius (GN) muscle at the side of the injection 
for both concentrated and dilute injection groups, but in ~100x higher amounts for the concentrated injection 
group. Elevated levels in the liver were found to be consistent with standard bioclearance mechanisms27. Because 
the cervical spinal cord was sampled for biodistribution, and because AAV6 is likely to transverse retrograde 
only one synapse to the lumbar spinal cord, we expected, and identified no significant levels of rAAV DNA in 
the spinal cord. The sciatic nerve, targeted during the injection, also showed little to no viral DNA. This finding 
indicated that viral particles must travel in a retrograde fashion up the nerve via an intracellular pathway and that 
Schwann cells adjacent to each axon were not transduced by rAAV.
Activated immune cells target ChR2-EYFP+ neurons in spinal cord. We previously reported 
increased cell density within spinal cord samples of AAV6 transduced optogenetic rats as measured by DAPI+ 
General Mechanism Specific Mechanism Description
Likely Singular 
Physical Manifestation Evidence in Literature
Direct Nerve Damage Phototoxicity Light-induced thermal damage
Axonal death + 
Wallerian Degeneration Khan et al.
13, Chen et al.39
Cytotoxicity
Excitotoxicity
Optogenetic pore-
induced electrostatic 
damage
Neuronal death via 
apoptosis
Beppu et al.15,Perny et al.16, 
Lignani et al.40, Feldbauer et al.41
ChR2 toxicity Toxicity of opsin build-up & aggregation
Neuronal death via 
apoptosis
Zimmerman et al.9, Gradinaru 
et al.10, Miyashita et al.6, Li et 
al.42
EYFP toxicity Toxicity of reporter build-up & aggregation
Neuronal death via 
apoptosis
Ansari et al.22, Taghizadeh et 
al.24
Immunogenicity
AAV immunogenicity Adaptive immune response to virus
Neuronal+ muscular 
death via CTL
Montgomery et al.1, Mingozzi et 
al.19, Sack et al.43, Kohro et al.17
ChR2 immunogenicity Adaptive immune response to opsin Neuronal death via CTL None
#
EYFP immunogenicity Adaptive immune response to reporter Neuronal death via CTL
Ansari et al.22, Stripecke et al.23 
Kohro et al.17
Protein Loss-of-Expression
Episomal DNA loss
rAAV DNA broken 
down or lost during 
division
Neuron likely healthy, 
no longer expresses McCarty et al.
44, Fisher et al.45
Epigenetic silencing
rAAV DNA silenced/
methylated (no longer 
transcribed)
Neuron likely healthy, 
no longer expresses
Robertson et al.46, Okada et al.47, 
Migliaccio et al.48
Transgene protein 
degradation or mRNA 
lysis/downregulation
Recombinant protein 
ubiquitinated 
and discarded via 
proteosome or no 
longer translated
Neuron likely healthy, 
no longer expresses Jennings et al.
49, Kong et al.50
Anatomical Anatomical More scattering in thick tissue
Neuron healthy, still 
expresses Jacques et al.
51, Maimon et al.4
Table 1. Comprehensive list of potential causes for loss of optogenetic expression over time. #Non-opsin 
transgene immunogenicity has been seen in AAV gene therapy19 and has been discussed as a concern for 
optogenetics52.
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fluorescence4. Here, we first evaluated H&E cross-sections of ChR2+ neurons in spinal cord samples; these 
cross-sections showed an ipsilateral inflammatory infiltrate predominately comprised of agranulocytes (Fig. 2a). 
We stained for CD8+ cytotoxic T lymphocytes (CTL) and discovered these CTLs appear to home to ChR2-EYFP 
transduced neurons directly (Fig. 2b); the ChR2+ neurons are surrounded by CTLs that otherwise are not present 
significantly within the gray matter of the spinal cord. To assess for further inflammation, we stained for CD68+ 
activated macrophages, and discovered an aggressive inflammatory infiltrate comprising many immune cells 
adjacent to the location of transduced ventral horn motor neurons (Fig. 2d).
We then explored sciatic nerve sections directly for evidence of immune cells (Fig. 2c). Although there was 
no significant evidence of increased cellularity, immunofluorescence for CD8+ lymphocytes revealed elevated 
CTLs scattered throughout the ipsilateral sciatic nerve expressing ChR2-EYFP, compared to only one CTL on 
the contralateral sciatic nerve. Within the injected muscle, there was distinctive evidence of denervation atrophy 
(Fig. 2e). Normal, healthy myocytes averaging 43 µm in diameter were found adjacent to distinctively shrunken 
myocytes averaging 19 µm in diameter. Comparatively, the contralateral TA did not show any evidence of 
shrunken myocytes (not shown). Despite the denervation atrophy, there was no evidence of inflammatory infil-
trate within ipsilateral TA H&E sections, indicating that the muscle tissue itself was not an immune target. Lastly, 
ventral root sections showed increased presence of activated macrophages within roots containing ChR2-EYFP+ 
axons, as opposed to contralateral roots (Fig. 2f). Together, these results strongly suggested that ventral horn 
motor neurons and ChR2-EYFP transduced axons were being attacked by components of the adaptive immune 
system, resulting in motor neuron death and denervation atrophy in the corresponding muscle.
ELISA shows ChR2-EYFP specific serum antibodies. Given the inflammatory infiltrate within spi-
nal cord samples, it was theorized that the adaptive immune system was recognizing specific components of 
either the AAV6 capsid or the ChR2-EYFP fusion protein within the transduced neurons, which generally are 
co-localized. We developed an ELISA to identify rat serum antibodies against ChR2-EYFP protein, which showed 
a strong AAV injection dose dependency (Supp. Fig. 1b, 2c). The normalized antibody levels of the rats injected 
with 3E12 vp was significantly higher (P = 7E-4) at roughly 0.4 compared to 0.1 in the rats injected with 3E10 
vp and 1E10 vp, suggesting the rats were developing an antibody response to the ChR2-EYFP fusion protein in a 
dose-dependent fashion.
Despite the high antibody titer, we could not yet conclude that adaptive immune response was actually caus-
ing a loss of optogenetic expression in the rats. After all, the ventral horn neurons being transduced by AAV6 are 
in the spinal cord, and the CNS is generally considered protected from immune responses via the blood-spinal 
cord barrier (BSCB). Further, the one animal that maintained transdermal optogenetic expression up to 72 weeks 
post-injection (Fig. 1d) was found to have elevated antibody levels as measured by a serum ELISA reading of 0.45, 
AAV 
Dose
Week Post-Injection
3 4 5 6 7 8 9 10
3E+12
1E+12
3E+11
1E+11
3E+10
1E+10
Age of 
Injection
Week Post-Injection
3 4 5 6 7 8 9 10
P2
P2 + 2wk
P2, P6, 
P10, P14
P2, 1wk, 
2wk, 3wk
Injection 
Location
Week Post-Injection
3 4 5 6 7 8 9 10
TA (2wk)
TA (P2 + 
2wk)
TA + s.n. 
(2wk)
TA + s.n. 
(P2 + 
2wk)
dc
ba
Experimental Plan
1. Inject AAV at varying
dosage, age, and location
2. Illuminate transdermal
weekly with laser + record
EMG
3. Illuminate exposed sciatic
nerve at 2, 4, and 6 weeks
4. Euthanize when animal has
lost transdermal
expression; must be at
least 8 weeks post-injection
1E+0
1E+1
1E+2
1E+3
1E+4
1E+5
1E+6AN
D
gnrep
seipo
C
A
N
D
6VAA
3E12 vp
3E10 vp
Threshold from Standard Curve
Threshold from Doroudchi et al.
1000 µV No response3 µV Animal died – complications from surg.
Transdermal Response
Week Following First AAV Injection
Rat # 3 4 5 6 7 8 9 10 11 … 15 … 24 … 44 … 72
TA + s.n. (P2 + 2wk) Rat #1
1000 µV No response3 µV Did not assess
72 weeks post-injection
Transderm. Sciatic Peroneal
Rat # Laser LED Laser LED Laser LED
TA + s.n. (P2 + 2wk) Rat #1
Figure 1. (a) Experimental plan for dosage, timing, and location of injection animals. (b) Logarithmic 
VRMS amplitude of Tibialis Anterior (TA) motor activity in response to 473 nm, 45 mW/mm2 transdermal 
illumination of the proximal tibia for 4 s at 5 Hz and 10 ms PW for different groups. (2wk = 2 week, P2 = 2 
day postpartum, s.n. = Sciatic Nerve) (c) Biodistribution results for 3E12 vp and 3E10 vp injected animals. 
(GN = Gastrocnemius Muscle, Nerve = Sciatic Nerve). n = 3 biologically independent samples for each group. 
(d) Time-course for Rat #1 in group TA + s.n. P2 & 2 wk. This animal did not lose transdermal expression up 
through 72 weeks post-injection, when rat was euthanized. Logarithmic VRMS activity at the sciatic and peroneal 
nerves at time of euthanasia with different illumination sources shown, as well as sciatic nerve cross-section 
showing ChR2+ axons (green) and DAPI (blue): scale bar = 30 µm.
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in line with other rats in his treatment group. If high antibody titer was directly causing loss-of-expression, we 
would expect this rat’s prolonged optogenetic activity to correlate with lower anti-ChR2-EYFP IgG levels. Lastly, 
we noticed that differences in the AAV6 injection timing or anatomical target had no significant effect on the 
overall ELISA antibody levels (PANOVA = 0.34), despite minor differences in optogenetic time-course within these 
groups, indicating that antibody levels did not perfectly correlate to loss of optogenetic activity (Supp. Fig. 1b). 
Together, these results suggested an immune response had occurred, but further experiments were required to 
identify conclusively if this immune response was causing loss-of-optogenetic expression or merely clearing dead 
neurons following cytotoxic or excitotoxic-mediated apoptosis.
Rag2−/− rats maintain optogenetic expression, implicating adaptive immunogenicity as key 
mechanism underlying loss of expression. To identify causality, Rag2−/− rats were employed. These rats 
were first phenotypically assessed to verify adaptive immune deficiency. Tail vein blood from WT and Rag2−/− 
Sprague Dawley rats at 6 weeks of age showed a significant difference in total white blood counts (WBC), driven 
predominately by lymphocyte deficiency in the Rag2−/− group (Supp. Fig. 2a). Since Rag2 deficiencies do not 
affect innate immune lymphocyte populations, we employed flow cytometry to determine the remaining Rag2−/− 
lymphocytes were CD3−, suggesting the lack of mature T cells (Supp. Fig. 2b). We then injected AAV6 as before 
Left Right
ChR2+ Neurons 0 4
CD68+ Monocytes 9 245
e
c
ba
f
d
R
L
Left Right
ChR2+ Neurons 0 5
CD8+ Lymphocytes 10 93
L
R
RL
L
R
Left Right
ChR2+ Axons 0 17
CD68+ Monocytes 7 24
L
R
L
R
R t.n. c.p.n.
Left Right
ChR2+ Axons 13 655
CD8+ Lymph. 1 21
Count Diam.
Normal Myocytes: 21 43 µm
Atrophied Myocytes: 44 19 µm
R
L
Cells per 1 mm2
Left Right
2,582 4,320
t.n.
c.p.n.
L
Figure 2. (a) Coronal lumbar H&E spinal cord section of ChR2-EYFP+ neurons in rat showing ipsilateral 
inflammation present. Scale bar = 80 μm. Experiment repeated 4 times with similar results. (b) Lumbar spinal 
cord cross-section immunohistochemistry for ChR2-EYFP (red), CD8 (brown), and hematoxylin (blue). Scale 
bar = 60 µm. Experiment repeated 3 times with similar results. (c) Sciatic nerve (R) and contralateral sciatic 
nerve (L) stained for ChR2-EYFP (green), CD8 (red), DAPI (blue), and background axons (magenta) with tibial 
(t.n.) and common peroneal (c.p.n.) nerve divisions labeled. Scale bar (R) = 250 µm; Scale bar (L) = 500 µm. 
Experiment repeated 2 times with similar results. (d) Lumbar spinal cord cross-section immunohistochemistry 
for ChR2-EYFP (red), CD68 (brown), and hematoxylin (blue). Scale bar = 60 µm. Experiment repeated 3 times 
with similar results. (e) Tibialis Anterior (TA) cross-section of ChR2-transduced rat showing myocytes which 
are healthy (arrowhead) and those with denervation atrophy (arrow): Scale bar = 60 µm. Experiment repeated 
3 times with similar results. (f) Ventral root cross-section immunohistochemistry for ChR2-EYFP (red), CD68 
(brown), and hematoxylin (blue). Scale bar = 20 µm. Experiment repeated 2 times with similar results.
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to transduce ventral motor neurons of Rag2−/− and WT rats and found that at 4 weeks post-injection, both 
groups had similar levels of optogenetic activation. EMG responses were present in 5/5 rats of similar magnitude 
(P = 0.31). However, by 12 weeks post-injection, 4/5 of the WT rats had lost all optogenetic responses to trans-
dermal illumination compared to 0/5 of the Rag2−/− rats (Fig. 3a). Further, the minimum illumination power 
required to activate the targeted peroneal nerve stayed relatively constant in the Rag2−/− rats, as compared to the 
WT rats, which stopped responding, even at maximum illumination power (Fig. 3b). This effectively ruled out 
anatomical changes alone, because the fluence change was not sufficient to prevent transdermal optogenetic acti-
vation of the nerve for Rag2−/− rats, the males of which were much larger than their WT female counterparts, all 
of whom had stopped responding to transdermal illumination. The EMG results correlated well with the immu-
nofluorescence findings which showed significantly greater counts of ChR2-EYFP+ axons in the sciatic nerves of 
Rag2−/− rats compared to the WT rats (Fig. 3e,f), as well as CD8+ lymphocytic inflammation only in the spinal 
cords of WT rats (Supp. Fig. 2d,e).
In agreement with the loss-of-expression findings, ipsilateral muscle atrophy was also found to be restricted to 
the WT rats (Fig. 3c). Ipsilateral muscles were 33 ± 9% reduced and 19 ± 8% reduced compared to contralateral 
muscle weights in the anterior and posterior compartments respectively for WT rats. Comparatively, Rag2−/− rats 
had muscle reductions of 6 ± 5% and 1 ± 5% for the same compartments respectively. Anterior compartment 
muscle mass reductions ranged from a high of 47% for WT Rat #3 to a low of 23% for WT Rat #1, which correlates 
precisely with their optogenetic expression profiles. WT Rat #3 was the first rat to lose expression and there-
fore may have had the strongest immune response; WT Rat #1 had yet to lose expression at the time of euthanasia 
and thus may have had the weakest immune response. These individual differences were also reflected in the 
ChR2-EYFP ELISA. At 6 weeks post-injection, the plasma antibodies against ChR2-EYFP were slightly larger in 
the WT group, compared to the Rag2−/− group (P = 0.29) (Fig. 3d). However, the highly immunogenic WT Rat 
#3 was the outlier, with more than 2X the WT group’s overall ChR2-EYFP specific plasma antibody levels at that 
time. By 12 weeks post-injection, the serum antibodies in the WT group increased significantly, reaching 6X the 
Rag2−/− group (P = 8E-4). At this time, WT Rat #1 was the outlier with roughly half of the antibody expression 
of the group as a whole, in line with the lower atrophy and maintained immunofluorescent axonal expression in 
this rat (Supp. Figure 2f).
To rule out excitotoxicity as a contributing factor to loss of expression, we found the WT excitotoxicity con-
trols showed similar results to the WT stimulated rats during terminal procedures. 4/4 WT rats showed no 
response to any transdermal illumination during terminal procedures compared to 0/4 of the Rag2−/− excitotox-
icity controls (Supp. Fig. 6a). Further, no significant muscle atrophy, nerve expression, or ELISA differences were 
found between stimulation and no-stimulation groups (Supp. Fig. 6b,d) as compared to the sigificant differences 
in muscle atrophy, nerve expression, and antibody levels between Rag2−/− and WT no-stimulation groups (Supp. 
Fig. 6b-d). This result suggests that the stimulation used in this experiment is insufficient to cause any excitotoxic-
ity mediated nerve damage or neuronal death. Together with the stimulation results, these data show conclusively 
that the adaptive immune system is a necessary condition for the loss of optogenetic activation over time and that 
a component of the AAV6-ChR2-EYFP immunogen is directly causing loss of expression.
Tacrolimus extends longevity of optogenetic expression in WT rats. To identify pharmacological 
candidates for extending the life of virally delivered optogenetic expression in a WT animal, two broad categories 
of FDA-approved drugs were evaluated: a monoclonal antibody against CD49d (PS2), also known as VLA-4 or 
α4 integrin, and a general immunosuppressant. As the murine analog of natalizumab, a treatment for Multiple 
Sclerosis (MS), PS2 was chosen for its anti-inflammatory effects in experimental autoimmune encephalomyelitis 
(EAE)29. Compared to the placebo, PS2 was not found to increase the longevity of optogenetic activation, with 
10/10 PS2 rats and 9/10 placebo rats losing all responsiveness to transdermal illumination by week 8 (Supp. 
Fig. 4a). Comparatively, the general immunosuppressant tacrolimus was found to increase signfiicantly the lon-
gevity of transdermal optogenetic expression with only 1/10 tacrolimus treated rats losing optogenetic respon-
siveness to transdermal illumination at week 8, compared to 9/10 placebo rats (Fig. 4a). Additionally, PS2 did 
not appear to have any effect on WBC counts (data not shown) as compared to tacrolimus, which significantly 
reduced monocyte and lymphocyte counts compared to placebo (Supp. Fig. 3a). Further, PS2 rats were found 
to have developed non-specific anti-antibody neutralizing antibodies, which may have precluded drug efficacy 
(Supp. Fig. 4c).
Similar to the Rag2−/− rats, all rats treated with tacrolimus or placebo responded well to transdermal illu-
mination at 4 weeks post-injection (Fig. 4a). However, at 6 weeks, only 5/10 of the placebo rats responded to 
transdermal illumination compared to 10/10 of the tacrolimus rats. By 8 weeks, only 1/10 placebo compared 
to 9/10 tacrolimus rats responded with muscle activity to transdermal illumination. This one outlier placebo 
rat continued to increase in expression strength until 12 weeks, whereas two of the tacrolimus rats (#3, #7) lost 
transdermal expression by 12 weeks. The minimum fluence rate to elicit electrophysiological spikes similarly 
showed increasing sensitivity of placebo rat #4 and maintained sensitivities of all tacrolimus rats except #3 and #7 
(Fig. 4b), which aligns precisely with the low ChR2+ axon counts in all placebo rats except #4 and high ChR2+ 
axon counts in all tacrolimus rats except #3 and #7 (Supp. Fig. 3b,e).
As with the WT rats, there was significant muscle atrophy within the anterior compartment of the placebo 
group of 38% as compared to 9% in the tacrolimus group (P = 3E-6) (Fig. 4c). The atrophy ranged from a high of 
57% to a low of 28% for the placebo rats and a high of 23% to a low of −6% for the tacrolimus rats, when omitting 
the three outliers: tacrolimus rats #3 and #7 & placebo rat #4, which had atrophy of 58%, 43%, and 6% respectively 
(Supp. Fig. 3c). Unlike the WT rats, the posterior compartments in both tacrolimus and placebo groups did not 
show any atrophy at all (3% and 1%), possibly indicating better targeting of the anterior compartment during 
the injection. Similar to the WT rats, the ELISA results in the placebo group support the findings of ChR2-EYFP 
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immune responses (Fig. 4d). At 6 weeks, the measured anti ChR2-EYFP plasma antibodies of the placebo group is 
small, increasing significantly by 12 weeks (P = 5E-5). At 12 weeks, the tacrolimus group maintained low plasma 
antibodies as compared to the placebo group (P = 3E-5) with tacrolimus rat #3 and placebo rat #4 as excep-
tions, in line with muscle atrophy and loss-of-expression profiles. These data show that tacrolimus can be used to 
increase significantly the length of optogenetic expression.
It is unclear exactly what precipitated the lack of immune response for outlier placebo rat #4. Of note, at 6 
weeks post-injection, this rat was found to be very anemic, with red blood cells (RBC), hemoglobin (Hb), and 
hematocrit (HCT) levels all 8 standard deviations below the average from the other 9 placebo animals (Supp. 
Fig. 3d). Interestingly, the only other rat which maintained expression at week 12 (WT rat #1) was also anemic 
at 6 weeks. This rat’s RBC, Hb, and HCT levels were found to be 5 standard deviations below the other 4 WT rats 
in its group (Supp. Fig. 3d). However, the white counts (including differentials) and platelet counts for these two 
outliers were not significantly different from counts of their respective groups (data not shown). In addition, we 
noticed that tacrolimus had an effect on hematological characteristics. Within the tacrolimus group, RDW was 
significantly elevated (P = 1E-3) along with a corresponding reduction in MCV (P = 9E-4) and MCH (P = 4E-3) 
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Figure 3. (a) Logarithmic VRMS amplitude of Tibialis Anterior (TA) motor activity in response to 473 nm, 
105 mW/mm2 transdermal illumination of the proximal tibia for 4 s at 5 Hz and 10 ms PW for Rag2−/− and 
WT rats treated with high dose AAV6. (b) Logarithmic minimum transdermal illumination power needed to 
elicit transdermal EMG spikes from TA: VRMS threshold set to 2.45 µV, which was empirically determined to 
be the max noise level of recordings. (c) Ipsilateral to contralateral side of injection muscle weight ratio at the 
time of euthanasia for high dose Rag2−/− and WT rats in both the anterior and posterior compartment muscle 
groups, representing primarily the TA and Gastrocnemius muscles respectively (n = 5 per group). P = 1E-3 
for Ant. Comp. and P = 3E-3 for Post. Comp. (d) Normalized ELISA comparing plasma antibodies against 
ChR2(H134R)-EYFP for Rag2KO and WT rats at 6 weeks post injection (n = 2 for Rag2KO, n = 5 for WT) and 
12 weeks post injection (n = 5 for both groups). P = 8E-4 for 12 week. WT Animal 3 was the only rat which lost 
transdermal optogenetic expression at week 6. WT Animal 1 was the only rat which maintained expression at 
week 12. In addition to being included in their respective groups, these animals are also shown separately.  
(e) ChR2-EYFP+ axon counts as percentage of total axons (left) and as absolutes (right) in tibial nerve (t.n.) 
and peroneal nerve (c.p.n.) divisions of sciatic nerve of WT and Rag2−/− rats (nRag2−/− = 8, nWT = 7): Pleft = 2E-4. 
Pright = 3E-3. On left, rats from excitotoxicity control group also included. WT Rat #4 sciatic nerve omitted 
because was not properly paraffin processed. (f) Sciatic nerve cross sections of representative Rag2−/− rat 
(left) and WT rat (right) labeled for ChR2-EYFP (green) and DAPI (blue). Scale barleft,right = 120 µm, Scale 
barcenter = 20 µm. Experiment repeated 3 times with similar results.
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compared to the placebo group (Supp. Fig. 3f). However, no significant anemia was present between the placebo 
and tacrolimus groups (PHct,Hb = 0.7), even when excluding outlier placebo rat #4. We can therefore conclude that 
tacrolimus is causing a reduction in the average erythrocyte size. Since this is occurring when tacrolimus con-
centration hits peak levels around 4 weeks of age, and knowing that the rat erythrocyte life is roughly 60 days30, 
we can conclude that the high RDW and low MCV may be explained by the combination of normal erythrocytes 
prior to and small erythrocytes following the administration of tacrolimus therapy.
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Figure 4. (a) Logarithmic VRMS amplitude of Tibialis Anterior (TA) motor activity in response to 473 nm, 
105 mW/mm2 transdermal illumination of the proximal tibia for 4 s at 5 Hz and 10 ms PW for rats treated 
with slow release tacrolimus pellet compared to rats treated with placebo pellet. (b) Logarithmic minimum 
transdermal illumination power needed to elicit transdermal EMG spikes from TA for tacrolimus-treated 
and placebo-treated rats: VRMS spike threshold set to 2.45 µV, which was empirically determined to be the 
max noise level of recordings. (c) Ipsilateral to contralateral side of injection muscle weight ratio at the time 
of euthanasia between tacrolimus and placebo rats for both the anterior and posterior compartment muscle 
groups, representing primarily the TA and Gastrocnemius muscles respectively (n = 8 for tacrolimus, 9 for 
placebo group). Tacrolimus rats #3 and #7 (which had lost expression at time of euthanasia), and placebo rat 
#4 (which maintained expression at time of euthanasia) were excluded, as shown in Supplemental Figures. 
P = 3E-6 for anterior compartment and P = 0.23 for posterior compartment. (d) Normalized ELISA comparing 
plasma antibodies against ChR2(H134R)-EYFP for WT rats at 6 weeks post injection (n = 10) and 12 weeks 
post injection (all others, n = 10). P = 5E-5 for 6 vs 12 week comparison. P = 3E-5 for tacrolimus vs. placebo 
comparison at 12 weeks. In addition to being included in their respective groups, rat #3 in tacrolimus group 
and rat #4 in placebo group are also shown separately as they are outliers in their respective groups. (e) ChR2-
EYFP+ axon counts as percentage of total axons in tibial nerve (t.n.) and common peroneal nerve (c.p.n.) of 
tacrolimus and placebo rats (nTacrolimus = 8, nPlacebo = 9): Pt.n. = 5E-3; Pc.p.n. = 1E-3. Tacrolimus rats #3 and #7 
(which had lost expression at time of euthanasia), and placebo rat #4 (which maintained expression at time of 
euthanasia) were excluded. (f) Sciatic nerve cross sections of representative Rag2−/− rat (left) and WT rat (right) 
labeled for ChR2-EYFP (green) and DAPI (blue). Scale barleft,right = 120 µm, Scale barcenter = 20 µm. Experiment 
repeated 7 times with similar results.
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CAG promoter rules out AAV capsid as primary cause of immune response. To identify the role 
of AAV capsid in precipitating an immune response, we evaluated the ChR2-EYFP injected under the CAG 
promoter. Unlike hSyn, CAG does not restrict ChR2 expression to neural tissue, which was shown by the unique 
spiking behavior following transdermal illumination of these rats (Fig. 5a). Whereas hSyn spikes are narrow and 
return to baseline within ~4 ms of activation, CAG spikes are wide and return to baseline ~20 ms following acti-
vation. The narrow coordinated spike at the beginning of an optogenetically activated CAG waveform represents 
direct neural firing – all myocytes are time-synced to depolarize at once. This is followed by wider-band activity 
from continual activation of the myocytes directly, which have different refractory dynamics as compared to 
axonal activation. This distinction is in agreement with our previous findings showing no motor activity following 
direct illumination of muscle in hSyn rats4 as compared to CAG rats, which showed exquisite motor control as 
would be expected with direct myocyte activation (Supplemental Video).
Unlike the hSyn animals, the CAG rats exhibited excessive mortality of 60% (Fig. 5b). Although necropsies 
did not reveal any specific cause of death, these animals overall had a lower weight than the WT rats and exhib-
ited more hunching and eye staining. Like the hSyn promoter the two surviving CAG rats lost strength of the 
EMG signal from week 4 to week 8 in terms of EMG levels. Unlike the hSyn promoter, an immunohistochemical 
analysis of the CAG TA showed significant ChR2+ myocytes. Not only were these myocytes spread throughout 
the section, there was lymphocytic inflammation specifically co-localized to the transduced myocytes (Fig. 5c). 
The biodistribution for CAG rats revealed levels of ChR2-EYFP DNA within both the CAG and hSyn muscle 
were very similar at ~1E5 copies per ng DNA (Supp. Fig. 5A). Therefore, given the identical AAV6 dosage and 
injection, and similar biodistribution results between the hSyn and CAG groups, the findings of high mortal-
ity and ChR2-EYFP specific myocyte inflammation in exclusively the CAG rats must indicate that the immune 
response is directly targeting ChR2-EYFP and not the AAV capsid. Since both hSyn and CAG promoters result in 
equivalent levels of AAV capsid fragment expression on myocytic MHCI, but only the CAG promoter results in 
myocytic immune attack, we can conclude immunogenicity is specific to the  ChR2-EYFP protein.
ChR2-only and ChR2-EYFP rats show equivalent immune activity, suggesting immune response 
is ChR2-specific. After determining the primary immunogen is ChR2-EYFP, we injected a last set of 10 rats 
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Figure 5. (a) Tibialis Anterior (TA) EMG recordings in response to 473 nm transdermal illumination of 
proximal tibia in rats transduced with rAAV-ChR2 restricted by either hSyn or CAG promoter. (b) Logarithmic 
minimum transdermal illumination power needed to elicit transdermal EMG spikes from TA for hSyn and 
CAG promoters: VRMS spike threshold set to 2.45 µV, which was empirically determined to be the max noise 
level of recordings. (c) TA cross-section of CAG rat 8 weeks post-injection showing healthy myocytes devoid of 
inflammation on contralateral limb (left) and ChR2-EYFP transduced myocytes co-localized with significant 
inflammatory cells on ipsilateral limb (red, right): scale bar = 40 µm. Experiment repeated 1 time with similar 
results. (d) Immunofluorescence for ChR2+ axons in CAG-ChR2-EYFP sciatic nerve sections along with 
counts in peroneal (c.p.n.) and tibial (t.n.) sections: scale bar = 20 µm. Experiment repeated 1 time with similar 
results.
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with AAV6-hSyn-ChR2 lacking the fluorescent reporter. Interestingly, these animals at 2 and 4 weeks expressed at 
significantly weaker levels than those containing the fluorescent reporter (P = 0.05) (Fig. 6a). Further, the move-
ment was qualitatively weaker (Supplemental Video), although the minimum fluence rates needed to activate 
the nerves at 4 weeks was similar (Fig. 6b). Because of the above, it is likely that fewer axons expressed func-
tional ChR2 at 4 weeks of age in absence of reporter, although 12 week ChR2+ axon counts were insignificantly 
different (Fig. 6e, Supp. Fig. 7a). Without reporters, fluorescent activity for all sciatic nerves ranged between 
0–2% of total axons with the exception of rats #2 and #7, which had peroneal transduction rates of 4% and 
9% of all axons respectively, which matches electrophysiological findings. Additionally, Rat #7 still expressed at 
the time of euthanasia, optogenetically responding to transdermal stimulation. The general finding of weaker 
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Figure 6. (a) Logarithmic VRMS amplitude of Tibialis Anterior (TA) motor activity in response to 473 nm, 
105 mW/mm2 transdermal illumination of the proximal tibia for 4 s at 5 Hz and 10 ms PW for rats injected with 
ChR2-only vs. those with ChR2-EYFP. (b) Logarithmic minimum transdermal illumination power needed to 
elicit transdermal EMG spikes from TA for ChR2-only and ChR2-EYFP rats: VRMS spike threshold set to 2.45 
µV, which was empirically determined to be the max noise level of recordings. (c) Ipsilateral to contralateral 
side of injection muscle weight ratio at the time of euthanasia between Rag2−/− and ChR2-only rats for both 
the anterior (A.C.) and posterior compartment (P.C.) muscle groups, representing primarily the TA and 
Gastrocnemius muscles respectively (n = 9 for Rag2−/−, n = 9 for ChR2 only). ChR2-only rat #7 (which had 
maintained expression at time of euthanasia) was also shown separately and excluded from significance test 
(PA.C. = 7E-5, PP.C. = 0.06). (d) Normalized ELISA comparing plasma antibodies against ChR2(H134R)-EYFP 
for WT rats at normal and low dose, Rag2−/− rats at normal dose, and ChR2(H134R) WT rats without reporter 
(nChR2-EYFP = 4, nChR2-EYFP low = 4, nChR2 only = 3, nRag2−/− = 5). Only ChR2-only rats who had lost all transdermal 
and subcutaneous expression at the time of blood collection were included. Pleft = 0.002; Pcenter = 0.12; 
Pright = 0.006. (e) ChR2-EYFP+ axon counts as percentage of total axons in tibial nerve (t.n.) and peroneal nerve 
(c.p.n.) of tacrolimus and no reporter rats (nTacrolimus = 8, nNoReporter = 9): Pt.n. = 0.02; Pc.p.n. = 4E-3. Tacrolimus 
rats #3 and #7 (which had lost expression at time of euthanasia), and no reporter rat #7 (which maintained 
expression at time of euthanasia) were excluded. Sciatic nerve cross sections of representative no reporter rat 
labeled for ChR2 (green) and DAPI (blue). Scale barbottom = 200 µm, Scale bartop = 30 µm. (f) Number of DAPI+ 
cells on ipsilateral side compared to contralateral side of spinal cord expressed as a percentage increase for WT 
(n = 3), Rag2−/− (n = 3), placebo (n = 3), tacrolimus (n = 3), and no reporter rats (n = 5). PANOVA = 8E-3. Can 
reject the null using Fisher’s LSD at α = 0.01 for ** and α = 0.05 for *.
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optogenetic activation in absence of reporter is in agreement with previously unpublished reports by other groups 
that the presence of the reporter itself increases the photocurrents of the opsin molecule, although the mechanism 
underlying this remains unclear.
As with the previous WT rats, ChR2-only rats revealed ipsilateral muscle loss in the anterior compartment 
of 23 ± 14% (Fig. 6c). Among the rats that lost expression in this group, muscle weight loss ranged from 35% in 
rat #1 & #10 to −5% in Rat #7, likely reflecting a drop in the number of optogenetically active motor neurons 
compared to the WT and placebo groups of same dosage. To verify this AAV did not contain EYFP, immuno-
fluorescence using antibodies against EYFP revealed no axons, whereas using antibodies against ChR2 yielded 
transduced axons (Supp. Fig. 7d). To verify immunogenicity as opposed to toxicity in the ChR2-only group, 
immunohistochemistry of axial spinal cord sections revealed both a high number of CD8+ lymphocytes on the 
injection side as compared to the contralateral side (Supp. Fig. 1b) and generally high cell densities on the ipsi-
lateral side (Supp. Fig. 7c). Further, the ELISA against ChR2 revealed a slight elevation of anti-ChR2 serum anti-
bodies in the no reporter group as compared to the Rag2−/− rats and non-injected control samples; however, the 
serum antibody level was significantly lower than those of the same dose ChR2-EYFP injections (Fig. 6d). Levels 
were insignificantly different from the antibody levels of the low-dose ChR2-EYFP injections in the WT rats. No 
reporter rat #7, which maintained expression at the time of euthanasia, had lower levels of plasma antibodies, 
in line with the non-injected sample. When high cell densities in the spinal cord were evaluated as a percentage 
increase over the contralateral side, placebo, WT, and no reporter rats all have significant ipsilateral inflammation 
compared to Rag2−/− and Tacrolimus treated groups: PANOVA = 8E-3 (Fig. 6f). Together, these results definitively 
implicate the ChR2 transgene protein as being the highly immunogenic cause of optogenetic loss-of-expression. 
In this experiment, the ChR2 transgene elicited a strong CTL-mediated PNS and CNS immune response resulting 
in loss of optogenetic activation, motor neuron death, and muscle atrophy.
The contribution of each experiment to the conclusive establishment of the immunogenic cause is outlined 
in Table 2. Although other factors are not conclusively ruled out as contributing to loss-of-expression, the results 
show that ChR2 immunogenicity is definitively causing loss of expression and motor neuron death; it is a prime 
concern for optogenetic time-course.
Discussion
In this experiment, we hypothesize that ChR2 immunogenicity is causing the loss-of-expression over time in 
Sprague Dawley and Fischer 344 rats. The data presented in this study support this hypothesis. To identify immu-
nogenicity, we employ Rag2−/− rats and identify sustained levels of transdermal optogenetic expression at 12 
weeks post-injection. Further, we use a slow-release tacrolimus to extend the time course of expression levels in a 
WT rat. We then study AAV-hSyn-ChR2 upon removal of the fluorescent reporter, and identify all the same signs 
of immunogenicity, suggesting ChR2 alone is still highly immunogenic.
Unlike previous studies, which have shown loss-of-optogenetic activity may be caused by AAV immuno-
genicity, EYFP toxicity, ChR2 excitoxicity, or other potential mechanisms, this is the first study to show that ChR2 
immunogenicity is directly causing loss-of-optogenetic activity in the CNS/PNS, neuronal death, and muscle 
atrophy. As a result, we raise some concerns regarding the application of ChR2 as a therapeutic tool. Perhaps 
optogenetic therapies should only be applied for CNS neurons that do not project into the PNS? Perhaps once 
foreign proteins in the CNS are recognized by the immune system, the Blood Brain Barrier (BBB) or BSCB 
become more permeable to immune cell passage? Perhaps early clinical translations of optogenetic therapies 
Potential Causes TA histology
Spinal 
Cord  IHC Sciatic IF
Rag2−/− 
Electrophys.
Excitotox. 
Control
Immuno-
suppression
CAG muscle 
histology
CAG 
mortality No Reporter
Phototoxicity + −
Excitotoxicity + −
ChR2 toxicity + −
EYFP toxicity + −
AAV immunogenicity + + + + + − −
ChR2 immunogenicity + + + + + + +
EYFP immunogenicity + + + + + + −
Episomal DNA loss − −
Epigenetic silencing − −
Transgene protein 
degradation or mRNA 
lysis
− −
Anatomical − − −
Rationale
Denervation 
atrophy suggests 
neuronal 
damage
CD8+ & 
CD68+ 
WBC 
home to 
ChR2+ 
Neurons
Axons 
healthy, 
with slight 
elevation 
of CTLs
5/5 Rag2−/− 
compared to 
1/5 WT with 
expression
WT rats low 
expression & 
pos. immune 
panel whether 
stim or not
Tacrolimus 
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expression & 
neg. immune 
panel
Inflammation 
only present 
in CAG-
ChR2-EYFP+ 
myocytes
AAV is 
same, but 
significant 
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in CAG rats
Loss of 
expression & 
pos. immune 
panel without 
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Table 2. Contribution of factors to conclusion of ChR2-specific immunogenicity.
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should recruit patients who are already immunocompromised instead of screening out those patients? Future 
scientific work and clinical work should aim to address these questions.
We develop a comprehensive panel of four tests that identify an optogenetic immune response. First, a novel 
ELISA identifies serum antibodies against ChR2 or ChR2-EYFP. We validate this ELISA using serum from an 
AAV-ChR2 dosage curve. The ELISA properly identifies group outliers, suggesting it may be a method of pre-
dicting loss-of-optogenetic-activity. Second, ipsilateral muscle atrophy as assessed by muscle weight is correlated 
with loss of expression. In the future, using muscle mass reduction to provide an estimate of transduction effi-
ciency may be more accurate than using nerve cross-sections, because nerve cross-sections may be biased by 
variability in branching of cutaneous, autonomic, or non-target muscle efferent nerve fibers. Third, immunoflu-
orescent observations of nerve fibers and spinal cord sections reveal elevated CD8+ lymphocytes and CD68+ 
macrophages co-localized to ChR2+ neurons and axons. Lastly, DAPI+ cell counts of contralateral and ipsilateral 
spinal cord sections show an increase of ipsilateral inflammatory cell density. Together, these four tests compre-
hensively constitute a peripheral optogenetic-specific immune panel, which can be employed as a benchmark in 
future scientific and clinical optogenetic studies.
We present thirteen potential mechanisms describing loss-of-optogenetic activity divided into five independ-
ent categories by mechanism of action: phototoxicity, cytotoxicity, immunogenicity, protein downregulation, and 
anatomy. While each of these mechanisms may play some role in loss-of-activity, our experiments suggest that 
ChR2 immunogenicity is the key contributor. To reach this conclusion, we first identify inflammation in spinal 
cord samples in certain WT rats. However, cellular apoptosis can also send damage signals and recruit inflam-
matory cells – spinal cord inflammation is not alone sufficient to rule out phototoxic, excitotoxic or cytotoxic 
mechanisms. The presence of CTLs and activated macrophages co-localized to ChR2+ neurons strongly suggests 
an adaptive immune process is occurring directly related to the AAV capsid or viral transgene. However, to prove 
this causatively, we employ Rag2−/− rats and find extended transdermal optogenetic activity in all Rag2−/− rats. 
We attempt to prolong optogenetic expression in WT rats and find that a subcutaneous slow-release tacrolimus 
pellet is an effective method to extend optogenetic expression. To rule out AAV capsid immunogenicity, we inject 
two WT groups with the identical AAV dose, using CAG and hSyn promoters to modulate tissue specificity. Not 
only does the CAG promoter result in significant mortality, but it also results in immune infiltrates co-localized 
with ChR2+ myocytes. Immune infiltrates do not occur within the ChR2- hSyn promoter myocytes, despite the 
identical presence of AAV capsid within muscle tissue as shown by the biodistribution, enabling us to conclude 
that the adaptive immune system is targeting the ChR2-EYFP protein specifically. Lastly, we perform AAV-ChR2 
injections without the EYFP reporter. We discover the same loss-of-expression time-course as with the EYFP 
reporter, allowing us to conclude that of the thirteen potential mechanisms, ChR2 immunogenicity is the chief 
cause.
In addition, we present outliers to the groups revealing unique insights for further study. One rat out of the 
fifty-four studied in the dosing, timing, and anatomy study maintained transdermal peripheral nerve expres-
sion for 72 weeks post-injection. This represents the longest-ever virally induced peripheral nerve optogenetic 
response to our knowledge, indicating that highly expressing long-term optogenetic stability is possible, even in 
the case of elevated levels of plasma anti-ChR2-EYFP antibodies. To understand why this might have been the 
case, we analyze hematological abnormalities of WT rat #1 and placebo rat #4, both of which maintain trans-
dermal expression when the other rats in their respective groups lose expression by week 12. It is interesting to 
note that both of these rats were significantly anemic at 6 weeks of age compared to other rats in their groups (P: 
~1E-18 and ~1E-7), despite no difference in WBC or thrombocyte counts. At this age, only a few rats had lost 
transdermal optogenetic expression, so the early anemia may be a predictive way of screening rats or potentially 
humans for their future time-course. A low HCT has been previously associated with a complete elimination 
of the symptoms of EAE31, which is a largely representative condition of the motor neuron spinal cord inflam-
mation seen here. These authors propose that iron deficiency may impair CD4+ T cell maturity, which is also 
suggested in another study showing human subjects with low iron levels were less responsive to an influenza 
vaccine32. Further, these authors also identify that their mice with a low HCT also have significantly elevated 
levels of IL-2, which helps promote development of CD25+ regulatory T cells. These regulatory cells may help 
temper the effects of the CD4+ and CD8+ T lymphocytes, preventing the spinal cord inflammation in the first 
place. It is unclear why these two rats are anemic to begin with; we do not believe that it has anything to do with 
the intervention itself, but rather by natural variation. It is possible that iron deficiency and/or HCT may be used 
clinically to help screen patients for better outcomes in future CNS gene therapy studies, but a better mechanistic 
understanding of the relationship is critical.
Conversely, tacrolimus rats #3 and #7 both lost expression compared to the other rats in their group. We 
show that these two rats had normal levels of RDW at 6 weeks compared to the placebo group (P = 0.3), but 
significantly lower when compared with the other rats in their own group (P = 4E-3). Previous research has 
shown a correlation between tacrolimus concentrations and RDW in blood samples from anemic transplant 
recipients33,34. This correlation was identified as important for proper titration of tacrolimus dosage in trans-
plant recipients with these authors proposing that RDW could be used to adjust tacrolimus dosage to the patient 
because “anisocytosis may affect the apparent plasma clearance of tacrolimus”. Our findings suggest the opposite, 
that tacrolimus is in fact causing the anisocytosis, in which case measures of RDW to predict tacrolimus dosage 
response may not be appropriate. Rats #3 and #7 may not have absorbed as much tacrolimus as evidenced by 
a positive immune panel (+serum antibodies, high muscle atrophy, low ChR2 nerve expression, and elevated 
ipsilateral spinal cord infiltrate) as well as their normal RDW readings. Mechanistically, further study of the 
cause-effect relationships of immunosuppressants and hematological abnormalities is warranted and may help 
improve outcomes for both organ transplant and future optogenetic therapy recipients.
In this study, we propose a pharmacological mechanism to extend optogenetic longevity for peripheral nerves. 
However, it is unclear to what extent the findings in this study are specific to peripheral nerves. Like the BBB, the 
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spinal cord is generally protected from immune attack by the BSCB, which can become dysfunctional in autoim-
mune conditions like MS35. However, we note inflammatory infiltrates directly within the spinal cord that resulted 
in the irreversible destruction of spinal motor neurons, likely leading to a permanent unilateral weakness in the 
optogenetic treated rats. Although this destruction of spinal motor neurons may present an opportunity for a new 
murine model of amyotrophic lateral sclerosis (ALS) based on optogenetics, it is an unnerving finding in the face 
of planned investigational studies for optogenetics within human peripheral nerves. If we were to inject the virus 
directly into the spinal cord, would we still identify the same immunogenicity? Given that hSyn properly restricts 
ChR2 expression to neural tissue and that spinal cord ventral motor neurons project out into the peripheral nerv-
ous system, we postulate that immunogenicity is more a function of dosage and cell type than injection location. 
Using components of the immune panel we developed specifically to screen for optogenetic immunogenicity in 
this study, we encourage future researchers to evaluate presence of plasma anti-ChR2 antibodies in response to 
optogenetic transduction directly within the brain and retina to determine whether our results are truly periph-
eral nerve specific.
Future work should focus on mitigating the immune response by designing opsins to evade immune recog-
nition. One strategy to approach this may be first to identify peptide fragments that are most immunogenic and 
then alter these regions with site-directed mutagenesis or alternative opsin sequence alignment. Other strategies 
could focus on the host, either optimizing the immunosuppression drug, dose, and time course or identifying if 
there is a causative link between anemia and optogenetic immunogenicity, using hematological strategies to evade 
immune recognition. A third strategy could employ anti-inflammatory constructs such as PD-L1/2 within the 
AAV DNA to reduce the danger signals required for T lymphocyte mediated cellular destruction36. Additionally, 
this study focused on injection of neonatal and young rats – it would be interesting to identify whether immuno-
suppression could improve expression in adults, a group more difficult to transduce with AAV. While this study 
represents an important discovery in optogenetics and neuroimmunology, it is also a humbling one – it under-
scores the importance of exhaustive safety and validation testing of new technologies prior to their clinical and 
commercial implementations.
Methods
All animal experiments were conducted on Fischer 344 or Sprague Dawley rats; all experimental protocols were 
approved by the Committee on Animal Care at the Massachusetts Institute of Technology. All methods were 
carried out in accordance with relevant guidelines and regulations.
Opsin Injection. Sprague Dawley (Horizon Discovery) or Fischer 344 (Charles River Labs) rats were injected 
at P2 (unless otherwise specified) with 15 µL AAV6-hSyn-ChR2(H134R)-EYFP-WPRE (unless otherwise spec-
ified). The use of the hSyn promoter restricted expression to neural tissue4. Virus was produced by Virovek, Inc 
from plasmids at a titer of 1 × 1014 vp/mL. Under isoflurane anesthesia, rats were injected under sterile conditions 
through a 34 G needle (WPI) attached to an intraocular kit (WPI), Silflex tubing (WPI), and a 10 μL nanofil 
syringe (WPI) on the UMP3 syringe pump (WPI) with injection rate set to 75 nL/s. Rats were housed under a 
12:12 light:dark cycle in a temperature-controlled environment with food and water ad libitum, and euthanized at 
either 8 or 12 weeks of age (unless otherwise specified). Each rat was analyzed for an optogenetic response either 
weekly or bi-weekly via transdermal illumination to a 105 mW/mm2 (unless otherwise specified) 473 nm DPSS 
laser (OptoEngine) at varying laser intensities and/or a transdermal 0.6 W 475 nm LED (XP-E2, Cree, Inc.). Both 
laser and LED were set to 5 Hz and 5% DC (unless otherwise specified), illuminating the skin at the proximal tibia 
transdermal to the peroneal nerve (unless otherwise specified).
Dosing, anatomy and timing groups. 54 Fischer 344 neonatal rats were split into several groups to test 
the effect of different viral dosages, injection location, and injection timing. To test the effect of dosage on expres-
sion levels, six groups of three P2 neonates were injected in the right lower limb – both AC and posterior com-
partment (PC) – with 15 µL of AAV6-hSyn-ChR2(H134R)-EYFP-WPRE at the following dosages in vp/mL: 3E11, 
1E12, 3E12, 1E13, 3E13, 1E14. ChR2(H134R) was chosen due its common usage in the rat peripheral nervous 
system3–5. Two weeks later, the TA on these animals was surgically exposed and rats were injected with another 
12 µL directly into the TA and 3 µL directly into the peroneal nerve at the end plate at the same viral concentra-
tion, reaching the following total vp injected: (1) 1E10, (2) 3E10, (3) 1E11, (4) 3E11, (5) 1E12, (6) 3E12. To test 
the effect of injecting in the nerve vs. the muscle, four groups of four rats each were injected with the same virus 
at 1E14 vp/mL in the following groups: (1) 10 µL in the TA at 2 weeks postpartum; (2) 8 µL in the TA and 2 µL in 
the peroneal nerve at 2 weeks postpartum; (3) 5 µL in the TA at P2 and 5 µL in the surgically exposed TA 2 weeks 
later; (4) 5 µL in the TA at P2, 4 µL in the surgically exposed TA and 1 µL in the peroneal nerve at 2 weeks later. 
To test for the effect of injecting in different ages, four groups of five rats each were injected with the same virus 
at 1E14 vp/mL in the following groups: (1) 10 µL in the TA at P2; (2) 5 µL in the TA at P2 and 4 µL in the exposed 
TA & 1 µL in the exposed peroneal nerve at 2 weeks; (3) 2.5 µL in the TA at P2, P6, P10, and P14; (4) 2.5 µL each 
in the TA at P2 & 1 week postpartum, and 2.0 µL in the exposed TA & 0.5 µL in the exposed peroneal nerve each 
at 2 weeks postpartum and 3 weeks postpartum. Sample sizes were chosen to identify broad expression patterns 
without the intent of making statistically significant conclusions between groups. Rats were also exposed at 4 and 
6 weeks to direct illumination of the surgically exposed sciatic nerve. Rats were euthanized when transdermal 
illumination no longer produced any electrophysiological spikes, at a minimum of 8 weeks. This represented 
8–12 weeks for all animals with the exception of one animal, which still expressed transdermal up to 72 weeks 
post-injection (Fig. 1a,b,d).
Rag2−/− and WT Groups. 28 Sprague Dawley neonates were divided into 6 groups. 9 WT and 9 Rag2−/− P2 
neonates received injections of 15 µL virus. Of these rats, (1) four WT and (2) four Rag2−/− rats comprised the 
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excitotoxicity control groups. These animals did not receive any light stimulation over the course of the 12 weeks 
except during terminal procedures. The remaining (3) five WT and (4) five Rag2−/− rats comprised the high-dose 
group. Lastly, (5) five WT and (6) five Rag2−/− P2 neonates received injections of 1.5 µL virus comprising the 
low dose group. Rag2−/− rats were housed in SCID caging; liberal use of bleach and Quatricide PV (Pharmacal) 
prevented infection during testing procedures. Further, all testing was transdermal in these groups, eliminating 
the need for surgery.
Drug screen groups. Thirty Sprague Dawley neonates were divided into three groups of 10 neonates each 
based on the slow-release pellet (Innovative Research of America) employed: Placebo, Tacrolimus (Sigma), and 
PS2 (Bio-X-Cell). Dosages were sourced from the literature: Tacrolimus: 5.0 mg/kg/day = 30 mg/pellet37, and PS2: 
0.95 mg/kg/day = 5.5 mg/pellet29,38. PS2 was lyophilized using isopropanol in dry ice to freeze liquid followed 
by 48 hour vacuum to sublimate ice crystals. All drug pellets were produced from powders, manufactured to 
release drug evenly over a 60-day period based on 100 g animal body weight per pellet using a proprietary matrix 
(Innovative Research of America). Each group of rats was housed separately. At P2, neonates were injected with 
15 µL virus. When rats reached 50 g at roughly 2 weeks of age, a 2–4 mm incision was made ~5 mm caudal to 
the right ear and each rat was implanted with a single pellet. At ~5 weeks of age, when male rats reached 175 g, 
and when female rats reached 125 g, an incision was made ~5 mm caudal to the left ear; each male rat was given 
two additional slow release pellets while each female rat was given only one additional slow release pellet. This 
accounted for the female weight being ~33% less than the male weight from 5 week up through the point of eutha-
nasia to maintain consistent dosing within a group.
CAG and No reporter groups. Five Fischer 344 rats were injected with 15 µL AAV6-hSyn-ChR2 
(H134R)-EYFP-WPRE and five Fisher 344 rats were injected with 15 µL AAV6-CAG-ChR2(H134R)-EYFP-WPRE, 
at the same 1E14 vp/mL dosage. These animals were tested every two weeks but additionally had one sur-
gery as described previously3 at week 4 post-injection to check for optogenetic activity directly on the sciatic 
nerve. These rats were euthanized at 8 weeks as opposed to 12 weeks. Three of the five CAG promoter rats 
within two different cages died at ~4 weeks. A necropsy was performed on one of these rats, which revealed 
no obvious cause of death. Lastly, for the no reporter group, 10 Sprague Dawley rats were injected with 15 µL 
AAV6-hSyn-ChR2(H134R)-WPRE, eliminating the EYFP construct. Five of these rats were randomly selected to 
be euthanized at 8 weeks and five of these rats were selected to be euthanized at 12 weeks to increase the chance 
of catching optogenetic activity within the nerve for immunofluorescence analysis.
Channelrhodopsin electrophysiology measurement. Laser and LED pulses were controlled using a 
myDAQ (National Instruments) controlled by the NI Elvis Function Generator and custom software written in 
MATLAB as described previously3. The presence of a foot twitch in response to illumination was evaluated both 
electrophysiologically and visually. To evaluate the presence of a twitch response electrophysiologically and sub-
sequently measure the strength of that response, four 30 G monopolar electromyography (EMG) needles (Natus 
Medical) were directly inserted through the skin into the gastrocnemius (GN) and tibialis anterior (TA) muscles 
of each rat for bipolar recording as described previously4. Needles were connected to a 20 kS/s multi-channel 
amplifier with a fixed 200x gain (IntanTech). The laser and LED were secured above the anesthetized animal 
to an assembly allowing for six degrees of freedom. The laser (OptoEngine) employed a beam of Gaussian 
cross-sectional profile and 3 mm diameter (1/e2), corresponding to a peak irradiance at the surface of the skin of 
105 mW/mm2 at a measured output power of 375 mW. Electrical signals controlling the laser amplitude, pulse 
width, and frequency were simultaneously recorded by the amplifier, enabling temporal synchronization of laser 
pulses and EMG. EMG data was processed in MATLAB.
Lysate Production and ChR2-EYFP ELISA. To obtain ChR2-EYFP protein, hippocampal cells from 
Swiss-Webster mice were cultured in DMEM (D6171, Sigma) containing 1% L-glutamine, 1% Pen-Strep, and 10% 
Fetal Bovine Serum in a 24 well plate. Cells were transduced with 2 μL AAV6-hSyn-ChR2(H134R)-EYFP-WPRE 
(Western Blot and ELISA) or 2 μL AAV6-hSyn-ChR2(H134R)-WPRE (Western Blot only) at 1E14 vp/mL 
(Virovek). After 72–96 hours, EYFP production was assessed with fluorescence microscopy. Wells of success-
fully expressing plates were washed with 500 μL of sterile ice-cold PBS and incubated with 300 μL of trypsin 
for 2–4 min at 37 °C. 700 μL of culturing media were added to deactivate the trypsin. Resultant solution was 
transferred to a conical tube and centrifuged at low speed (650 g) for 5 min at 4 °C. Supernatant was decanted 
and cell pellet was gently resuspended in 1 ml of ice cold PBS. Solution was centrifuged at low speed (650 g) for 
5 min at 4 °C and supernatant was decanted. Cell pellet was resuspended in 400 μL cell lysis buffer (ThermoFisher 
Scientific) with 40 μL protease inhibitor cocktail (P8340, Sigma), incubated for 30 min on ice, and then centri-
fuged for 10 min at 12000 RPM at 4 °C. The supernatant was decanted and frozen at −80 °C until use. Western blot 
was used to verify presence of EYFP (ab290, Abcam) and ChR2 (anti-ChR2, American Research Products) within 
lysate samples via co-localized bands at ~62 kDa (Supp. Fig. 1a).
To measure serum IgG to ChR2-EYFP, a sandwich capture ELISA was developed on 96 well polystyrene plates 
(Nunc MaxiSorp, ThermoFisher Scientific). 100 μL/well pAb rabbit anti-GFP (ab290, Abcam) at a 1:500 dilution 
in PBS was used as the capture Ab and incubated overnight at 4 °C, followed by blocking with 5% skim milk in 
PBS-T for 1 hour at room temperature in a rocking platform. 40 μL lysate containing ChR2-EYFP was incubated 
per well for 3 hours at room temperature in a rocking platform. ELISA validation was performed at 1:3 lysate 
dilution in PBS whereas most sample measurements were performed at 1:20 dilution in PBS. A standard curve 
of absorbance for a variety of samples at 1:3 and 1:20 lysate dilution showed a linear trend with R2 = 0.97 (Supp. 
Fig. 1b). All reported values in this manuscript have been scaled to the predicted 1:3 lysate dilution.
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40 μL detection antibody was added to each well for 2 hours, consisting of either mAb mouse anti-ChR2 
(American Research Products, Inc.) diluted at 1:10 in blocking solution for positive controls or rat plasma sam-
ples. To identify optimal plasma dilution, samples were tested undiluted, at 1:30, and at 1:900 dilution in PBS sug-
gesting that no dilution gave the greatest sensitivity between test groups (Supp. Fig. 1d). 100 μL HRP-conjugated 
goat anti-rat or anti-mouse secondary antibodies (ThermoFisher Scientific) diluted at 1:2500 in PBS was incu-
bated per well for 1 hour. Lastly, 100 μL of 0.5 mg/mL OPD (ThermoFisher Scientific) in 90% deionized water 
and 10% stable peroxide substrate buffer (ThermoFisher Scientific) was added to each well. In between each step, 
wells were washed 3X for 5 minutes each with 100 μL PBS-T, except for the step prior to OPD, which required 5X 
washes. Absorbance at 450 nm was measured 15 minutes following the addition of OPD using a SpectraMax M5e 
plate reader (Molecular Devices). To account for inter-plate variability, each plate was linearly scaled relative to a 
negative serum control (serum from a non-transduced rat) and a repeated high-expressing serum sample from 
the same animal.
Biodistribution. Tissues for the biodistribution study were sourced from the Fischer 344 rats in the 3E12 and 
3E10 dosage groups (n = 3 each) as well as the CAG group (n = 2). The tissues investigated included brain, heart, 
liver, kidney, cervical spinal cord, lungs, ipsilateral axillary lymph node, spleen, gastrocnemius, sciatic nerve, con-
tralateral gastrocnemius, and contralateral sciatic nerve. All tissues were harvested at 8 weeks, snap-frozen and 
stored in microcentrifuge tubes at −80 °C. 5 mg of tissue was sampled from each collected specimen and DNA 
extraction from the various organs was performed using DNeasy Tissue Kit (Qiagen) with the addition of RNase to 
obtain pure DNA. DNA yields were quantified using Qubit Fluorometric Quantitation (ThermoFisher Scientific). 
Viral DNA was assessed by quantitative PCR (employing an absolute quantification method with a standard 
curve) on the DNA extract. After primer screening, two sets specific for ChR2 coding sequence were employed: 
Primer I (HPLC purified): (F) 5′-CAATGTTACTGTGCCGGATG-3′, (R) 5′-ATTTCAATGGCGCACACATA-3′, 
Primer II: (F) 5′-GCCTACCAAACCTGGAAATCTA-3′, (R) 5′-CTGTGGCAAGGTAGAGCATAG-3′). Samples 
were retained and used in parallel to analyze both 5 ng (once) and 15 ng (twice) of DNA in triplicates from each 
tissue. The standard curve was prepared with viral DNA, extracted from the viral particles themselves and puri-
fied using the same DNA extraction kit, with 5 mg GN tissue from non-injected control rat for purpose of tissue 
sample mimicry. Negative controls comprised control (non-injected) rat genomic DNA from the same set of 
tissues. 40 cycles were run on Roche Light Cycler 480 using SYBR Green I dye chemistry from KAPA SYBR Fast 
qPCR Master Mix (KAPA BIOSYSTEMS), followed by a melting curve for specificity analysis. The threshold was 
defined as 66 ChR2 copies per ng of tissue DNA, based on the limit of the dynamic range of the standard curves 
from all 3 runs. This level is similar to the previously mentioned biodistribution study25, which set a threshold of 
20 copies of beta actin for every viral copy as a threshold, which corresponds to roughly 20 copies/ng DNA in our 
study, below the confidence of the standard curve.
Tissue and sample processing, histology, immunohistochemistry, flow cytometry, and analysis. 
Blood collection at 6 weeks was done via tail vein draw of ~0.5 mL. Following EMG recordings during terminal 
procedures, ~0.5 mL blood was collected from rats via cardiac puncture. K3EDTA was used for anticoagulation 
(Minicollect, Greiner Bio-One). Rats were euthanized via intra-peritoneal sodium barbital followed by transcar-
dial perfusion with 60 mL PBS followed by 60 mL 4% PFA in PBS. Both AC and PC muscle groups on ipsilateral 
and contralateral legs were carefully dissected, cut from their origin and insertion points, and weighed. Spinal 
cord, ipsilateral TA, and ipsilateral sciatic nerve were dissected, fixed for 24 hours, paraffin processed, embedded, 
and cross-sectioned at 10 µm. Spinal cord was sectioned in either axial or coronal orientation.
Complete blood counts (CBCs) were performed with automated differential (Hemavet 950SS, Drew 
Scientific). For flow cytometery samples, blood was diluted by 1X in PBS and then spun down (650 g, 15 min) 
over Lymphoprep (Stem Cell Technologies). White blood cells predominantly comprising peripheral blood mon-
onuclear cells (PBMCs) were collected from phase layer, spun down again in PBS (650 g, 5 min). Supernatant was 
decanted and 500 µL PBS containing 1% BSA was added to resuspend PBMCs followed by 1.25 µL PE-conjugated 
Ms mAb to CD3 (ab95509, Abcam) or 1.6 µL isotype control (ab172730, Abcam). After a 30-minute incuba-
tion at 4 °C, samples were spun once again, supernatant was discarded, and 100 µL PBS containing 1% BSA was 
added to each sample followed by resuspension. Samples were incubated overnight at 4 °C. Flow Cytometry (BD 
FACSCelesta) was used to identify CD3+ lymphocytes. For non-flow cytometry samples, blood was spun down 
(650 g, 15 min), plasma was collected and frozen at −80 °C.
For immunofluorescence and immunohistochemistry, EYFP expression was amplified with Rb pAb anti-GFP 
(ab290, Abcam) at 1:200 or Gt pAb anti-GFP (ab6673, Abcam) at 1:100 with either anti-Rb or anti-Gt Alexa 
Fluor 488 (Fisher) or anti-Rb or anti-Gt AP (Biocare) and Vulcan Fast Red (Biocare). Expression of ChR2 was 
amplified with Ms anti-ChR2 at 1:50 (American Research Products, Inc.) and anti-Ms Alexa Fluor 488 (Fisher). 
Immunohistochemistry and immunofluorescence of inflammatory infiltrates employed Ms mAb anti-CD8α 
(ab33786, Abcam) or Ms mAb anti-CD68 (ab31630, Abcam) with either anti-Ms Alexa Fluor 568 (Fisher) or 
Goat anti-Ms HRP (GHP516, Biocare) with DAB (DB801, Biocare). All antibodies were diluted in 1% w/v BSA 
in PBS-T. Immunofluorescence images were taken on an Evos FL Auto epifluorescence microscope (Fisher) at 
10x (spinal cord) or 20x (sciatic nerve). H&E and immunohistochemistry images were taken on a digital slide 
scanner (Aperio AT2, Leica) at 20x. Using ImageJ, opsin+ axons were counted manually whereas total axon counts 
were estimated from representative counts of subsets of the nerve. Assessment of spinal cord inflammation was 
performed on ImageJ 10X DAPI+ sections using the freehand selection tool to choose equivalent areas of ventral 
horn gray matter on left and right coronal lumbar sections. The ImageJ process employed inversion, thresholding, 
conversion to masks, watershedding, and the “analyze particles” function with size limits set to 30–250 square 
pixels per cell. The number of total particles (corresponding roughly to the number of cells) was scaled to the total 
measured area of each selection.
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Statistical analysis. Statistical significance was calculated in Microsoft Excel with the data analysis toolbox. 
For comparisons of individual groups, student’s two-tailed t-tests with unequal variance were performed. For 
comparisons of multiple groups, a single factor analysis of variance (ANOVA) was performed followed by post 
hoc Fisher’s Least Significant Difference (LSD) test for significance. All data represent the mean ± s.d. of at least 
three independent experiments unless otherwise specified; the number of trials is reported in the data provided.
Code availability. The MATLAB.m code used for the temperature simulation, EMG processing and MC 
simulation are available from the corresponding author upon reasonable request.
Data Availability
The authors declare that all data supporting the findings of this study are available within the manuscript and its 
supplementary information.
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